We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Artemis Therapeutics Inc (PK) | USOTC:ATMS | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.498 | 0.181 | 0.50 | 0.00 | 01:00:00 |
☑
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
DELAWARE
|
84-1417774
|
(State or other jurisdiction of
|
(I.R.S. Employer Identification No.)
|
incorporation or organization)
|
|
18 East 16th Street, Suite 307, New York, NY
|
10003
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.01 per share
|
ATMS
|
OTCQB
|
|
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
Emerging growth company ☐
|
|
|
|
PAGE
|
|
|
|
4
|
||
|
|
|
4
|
||
|
|
|
|
5
|
|
|
|
|
|
6
|
|
|
|
|
|
7
|
|
|
|
|
|
8 | |
|
|
|
|
9
|
|
|
|
|
20
|
||
|
|
|
22
|
||
|
|
|
22
|
||
|
|
|
22
|
||
|
|
|
23
|
|
PAGE
|
|
|
5
|
|
|
|
6
|
|
|
|
7
|
|
|
|
8 | |
|
|
9-19
|
|
As of
March 31, |
As of
December 31,
|
|||||||||
|
Note
|
2020
(Unaudited)
|
2019
(Audited)
|
||||||||
|
|||||||||||
ASSETS
|
|||||||||||
|
|||||||||||
Current assets
|
|||||||||||
Cash and cash equivalents
|
2
|
2
|
|||||||||
Other accounts receivable and prepaid expenses
|
11
|
20
|
|||||||||
Total current assets
|
13
|
22
|
|||||||||
|
|||||||||||
TOTAL ASSETS
|
13
|
22
|
|||||||||
|
|||||||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|||||||||||
|
|||||||||||
Current liabilities
|
|||||||||||
Accrued expenses and other payables
|
163
|
157
|
|||||||||
Total current liabilities
|
163
|
157
|
|||||||||
|
|||||||||||
Long term liabilities
|
|||||||||||
Related Parties
|
8
|
105
|
103
|
||||||||
|
|||||||||||
Total Liabilities
|
268
|
260
|
|||||||||
|
|||||||||||
Shareholders’ equity
|
|||||||||||
Series A Convertible Preferred stock, $0.01 par value - Authorized: 10,000,000 shares; issued and outstanding: 453 shares as of March 31, 2020 and December 31, 2019
|
(*
|
)
|
(*
|
)
|
|||||||
Series C Convertible Preferred stock, $0.01 par value - Authorized: 250 shares; issued and outstanding: 250 shares as of March 31, 2020 and December 31, 2019
|
(*
|
)
|
(*
|
)
|
|||||||
Common stock, $0.01 par value - authorized: 51,000,000; issued and outstanding: 5,153,461 as of March 31, 2020 and December 31, 2019
|
52
|
52
|
|||||||||
Additional paid in capital
|
7
|
1,911
|
1,907
|
||||||||
Accumulated deficit
|
(2,218
|
)
|
(2,197
|
)
|
|||||||
Total stockholders' equity
|
(255
|
)
|
(238
|
)
|
|||||||
|
|||||||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
13
|
22
|
|
Three Months Ended
March 31, |
||||||||||
|
2020
|
2019
|
|||||||||
|
Note
|
(Unaudited)
|
|||||||||
|
|||||||||||
Research and development expenses
|
-
|
-
|
|||||||||
|
|||||||||||
General and administrative expenses
|
19
|
20
|
|||||||||
|
|||||||||||
Operating loss
|
19
|
20
|
|||||||||
Finance expense
|
2
|
1
|
|||||||||
Net loss
|
21
|
21
|
|||||||||
|
|||||||||||
Net loss per share, basic and diluted
|
6
|
0.003
|
0.003
|
||||||||
|
|||||||||||
Weighted average number of common stock used in calculation of net loss per share:
|
|||||||||||
Basic and diluted
|
5,153,461
|
5,153,461
|
Common Stock
|
Preferred Stock A
|
Preferred Stock C
|
Additional
paid-in Capital
|
Accumulated deficiency
|
Total
stockholders'
Equity
|
|||||||||||||||||||||||||||||||
|
Number
|
USD
|
Number
|
Amount
|
Number
|
Amount
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2019
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,907
|
(2,197
|
)
|
(238
|
)
|
|||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Share based compensation
|
-
|
-
|
-
|
-
|
-
|
-
|
4
|
-
|
4
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(21
|
)
|
(21
|
)
|
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Balance as of March 31 2020
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,911
|
(2,218
|
)
|
(255
|
)
|
Common Stock
|
Preferred Stock A
|
Preferred Stock C
|
Additional
paid-in Capital
|
Accumulated deficiency
|
Total
stockholders'
Equity
|
|||||||||||||||||||||||||||||||
|
Number
|
USD
|
Number
|
Amount
|
Number
|
Amount
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2018
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,571
|
(1,920
|
)
|
(297
|
)
|
|||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Adoption of new accounting Standards
|
-
|
-
|
-
|
-
|
-
|
-
|
319
|
(156
|
)
|
163
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Share based compensation
|
-
|
-
|
-
|
-
|
-
|
-
|
4
|
-
|
4
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(21
|
)
|
(21
|
)
|
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Balance as of March 31, 2019
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,894
|
(2,097
|
)
|
(151
|
)
|
|
Three Months Ended
March 31, |
|||||||
|
2020
|
2019
|
||||||
|
||||||||
Net cash used in operating activities
|
||||||||
Net (loss)
|
(21
|
)
|
(21
|
)
|
||||
|
||||||||
Share based compensation expenses
|
4
|
4
|
||||||
Decrease in other accounts receivable and prepaid expenses
|
9
|
4
|
||||||
Increase (decrease) in accrued expenses and other payables
|
6
|
8
|
||||||
Net cash used in operating activities
|
(2
|
)
|
(5
|
)
|
||||
|
||||||||
Cash flows from financing activities
|
||||||||
Related party loan
|
2
|
20
|
||||||
|
||||||||
Increase (decrease) in cash and cash equivalents
|
0
|
15
|
||||||
Cash and cash equivalents at the beginning of the period
|
2
|
7
|
||||||
|
||||||||
Cash and cash equivalents at the end of the period
|
2
|
22
|
|
A. |
Description of Business
|
|
B. |
Establishment of Artemis (the "accounting acquirer"):
|
|
C. |
Going Concern:
|
|
A. |
Unaudited Interim Financial Statements
|
|
B. |
Use of estimates in the preparation of financial statements:
|
|
C. |
Cash and cash equivalents
|
|
D. |
Fair value of financial instruments
|
|
E. |
Basic and diluted net loss per share
|
|
F. |
Research and development expenses, net
|
|
G. |
Income Tax
|
|
H. |
Share-based compensation
|
|
I. |
Recent Accounting Standards
|
|
A. |
Tax rates applicable to the income
|
|
B. |
Deferred income taxes
|
|
As of
March 31, 2020
|
As of
December 31,
2019
|
||||||
|
||||||||
Deferred tax assets:
|
||||||||
Deferred taxes due to carryforward losses
|
2,883
|
2,879
|
||||||
|
||||||||
Valuation allowance
|
(2,883
|
)
|
(2,879
|
)
|
||||
|
||||||||
Net deferred tax asset
|
-
|
-
|
C.
|
Tax loss carry-forwards
|
|
As of
March 31, 2020
|
As of
December 31,
2019
|
||||||
Israel
|
4,887
|
4,887
|
||||||
United States (*)
|
8,378
|
8,358
|
||||||
|
||||||||
|
13,265
|
13,245
|
Issuance
date |
|
Number of warrants
outstanding as
March 31, 2020
|
|
|
Exercise
price |
|
Exercisable
through |
||
|
|
|
|
|
|
|
|
||
October 2017
|
|
|
275,000
|
|
|
$
|
2.00
|
|
October 2022
|
|
Three Months
Ended March 31
|
|||||||
|
2020
|
2019
|
||||||
|
Unaudited
|
|||||||
Net loss available to stockholders of the company
|
(21
|
)
|
(21
|
)
|
||||
Net loss attributable to stockholders of preferred shares
|
(3
|
)
|
(3
|
)
|
||||
|
||||||||
Net loss used in the calculation of basic loss per share
|
(18
|
)
|
(18
|
)
|
||||
|
||||||||
Net loss per share
|
(0.003
|
)
|
(0.003
|
)
|
||||
|
||||||||
Weighted average number of common stock used in the calculation of net loss per share
|
5,153,461
|
5,153,461
|
|
A. |
Stockholders Rights:
|
|
B. |
Issuance of Shares
|
|
B. |
Issuance of Shares (Cont.)
|
|
C. |
Options issued to employees and consultants
|
|
D. |
Options issued to employees and consultants (Cont.)
|
|
For the Three months ended
March 31, 2020
|
|||||||||||
|
Number of stock options
|
Weighted average exercise price
|
Aggregate intrinsic value
|
|||||||||
|
||||||||||||
Outstanding at beginning of period
|
141,528
|
0.47
|
3,844
|
|||||||||
Granted
|
-
|
-
|
-
|
|||||||||
Exercised
|
-
|
-
|
-
|
|||||||||
Cancelled
|
-
|
-
|
-
|
|||||||||
|
||||||||||||
Outstanding at end of period
|
141,528
|
0.47
|
3,844
|
|||||||||
Options exercisable at period end
|
118,611
|
0.30
|
3,844
|
|
D. |
Options issued to employees and consultants (Cont.)
|
Exercise price
|
Stock options outstanding as of March 31,
|
Stock options outstanding as of December 31,
|
Weighted average remaining contractual life – years as of March 31,
|
Weighted average remaining contractual life – years as of December 31,
|
Stock options exercisable as of March 31,
|
Stock options exercisable as of December 31,
|
||||||||||||||||||||
$
|
2020
|
2019
|
2020
|
2019
|
2020
|
2019
|
||||||||||||||||||||
0.01
|
91,528
|
91,528
|
6.40
|
6.65
|
91,528
|
91,528
|
||||||||||||||||||||
1.30
|
50,000
|
50,000
|
7.96
|
8.21
|
27,083
|
23,958
|
||||||||||||||||||||
0.83
|
141,528
|
141,528
|
6.92
|
7.17
|
118,611
|
115,486
|
EXHIBIT
NUMBER
|
|
DESCRIPTION
|
|
|
|||
|
|
|
|
|
|||
|
|
|
|
101.1
|
|
The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 formatted in XBRL (eXtensible Business Reporting Language): (i) the Interim Condensed Consolidated
Balance Sheets, (ii) the Interim Condensed Consolidated Statements of Comprehensive Loss, (iii) the Condensed Consolidated Statements of Shareholders Equity, (iv) the Interim Condensed Consolidated Statements of Cash Flows and (v) related
notes to these financial statements, tagged as blocks of text and in detail.*
|
|
ARTEMIS THERAPEUTICS, INC.
|
|
|
|
|
|
|
Dated: May 14, 2020
|
By:
|
/s/ Chanan Morris
|
|
|
|
Chanan Morris
|
|
|
|
Chief Financial Officer
|
|
|
|
(Principal Executive Officer and
Principal Financial and Accounting Officer)
|
|
1 Year Artemis Therapeutics (PK) Chart |
1 Month Artemis Therapeutics (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions